Kantonsspital St. Gallen

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Retrieved on: 
Tuesday, May 30, 2023
Software, Radiology, Hardware, Health, FDA, Artificial Intelligence, Health Technology, Technology, Omni, CNR, GE HealthCare, Injection, Radiation, NEMA, DL, Molecular imaging, Deep learning, GE, PET, CHO, Quantification (science), Nuclear medicine, Doctor of Philosophy, Time of flight, National Association Medical Staff Services, US, Discovery, Kantonsspital St. Gallen, Acquisition, MD, Patient, Machine learning, AIR, Division, SNR, PET/CT, CR, Liver, AI, US FDA, A, European Journal, European Journal of Nuclear Medicine and Molecular Imaging, Medical imaging, Television, Silviculture, Imaging

GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio.
  • Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratioi, contrast recoveryi, and quantitative accuracyii.
  • Image quality matters – to the clinician and the patient – making the difference between finding a small lesion early or in its later stages, potentially affecting patient outcomes and disease management.
  • For this reason, clinicians are increasingly adopting AI-based solutions for enhanced image quality compared to that of standard care.

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, Infectious Diseases, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Pays de Herve, Amyotrophic lateral sclerosis, Geneva University Hospitals, ALS, Patent, Patient, DNA, PASC, MS, Degenerative disease, Centre hospitalier, Multiple sclerosis, COVID-19, Euronext Paris, Pharmaceutical industry, Kantonsspital St. Gallen

GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.

Key Points: 
  • GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
  • It has rights to 17 patent families protecting its technology.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005201/en/

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

Retrieved on: 
Wednesday, November 16, 2022
Health, Infectious Diseases, Hospitals, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Pays de Herve, Amyotrophic lateral sclerosis, Geneva University Hospitals, ALS, Patent, Patient, DNA, PASC, MS, Degenerative disease, Centre hospitalier, Multiple sclerosis, COVID-19, Euronext Paris, Pharmaceutical industry, Kantonsspital St. Gallen

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubnden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuros web site).

Key Points: 
  • GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubnden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuros web site).
  • GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
  • It has rights to 17 patent families protecting its technology.

OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

Retrieved on: 
Thursday, May 26, 2022
Microbiology, Risk, Kantonsspital St. Gallen, Nasdaq, Infection, Teaching hospital, Patient, Bronchoalveolar lavage, Randomized controlled trial, Pneumonia, HPN, Flagship, Adult, Mortality, BAL, Culture, Gram, Safety, Bronchoscopy, Gram-negative bacteria, PCR, Precision medicine, GLOBE, Medicine, Pharmaceutical industry

The Unyvero results for Gram-negative bacteria were disclosed to the attending physician treating the patients in the intervention group approximately 5 hours after bronchoscopy.

Key Points: 
  • The Unyvero results for Gram-negative bacteria were disclosed to the attending physician treating the patients in the intervention group approximately 5 hours after bronchoscopy.
  • In this study, they showed that Unyvero has a higher sensitivity than conventional microbiological culture when clinical syndrome or imaging is used as the reference standard.
  • OpGen, Inc.(Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding the publication of results of a recent clinical study of the Unyvero Hospitalized Pneumonia panel.

Thermo Fisher Scientific Calls for Grant Proposals to Support Research in Cancer Molecular Profiling

Retrieved on: 
Monday, February 28, 2022
Research, Medical Devices, Genetics, Philanthropy, Biotechnology, Health, Other Philanthropy, Science, Oncology, Thermo Fisher Scientific, Health, Fisher Scientific, Catholic University of Korea, University of Calgary, Liquid biopsy, Invitrogen, Applied Biosystems, Hospital, University, PPD, Laboratory, Catholic higher education, Mindful Scientific Inc., Biomarker, Kantonsspital St. Gallen, Science, Pharmaceutical Services Negotiating Committee, NGS, Cancer, Hematological Cancer Research Investment and Education Act, Combined small-cell lung carcinoma, Patient, Technology, Hospital das Clínicas, Patheon, Research, Program, Fisher, Medical imaging, Pharmaceutical industry

As part of its ongoing commitment to support clinical oncology research, Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant .

Key Points: 
  • As part of its ongoing commitment to support clinical oncology research, Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant .
  • The latest request for submissions from the global scientific community will award funding for molecular profiling research that helps accelerate the use of genomic sequencing in oncology.
  • The recipients of the grants will each be awarded up to $200,000 in reagents and general funding for independent clinical research proposals that demonstrate excellence in cancer molecular profiling.
  • The Oncomine Clinical Research Grant program aims to fund research furthering our understanding of cancer at the genomic level.